IP Library Granted Patent US 7,393,545
Granted Patent B2
US 7,393,545 · App. 10/602,955 · Granted Jul 1, 2008

Lipstatin derivative—soluble fiber tablets

Assignee: SmithKline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,393,545
App. No.
10/602,955
Granted
Jul 1, 2008
Kind
B2
Abstract

The present invention relates to a novel pharmaceutical composition and process for preparing swallowable rapidity disintegrating methylcellulose and lipstatin derivatives together in combination with a suitable diluent and excipients.

Claims (10)

1. A pharmaceutical composition for a tablet comprising: (a) at least one water soluble, non-fermentable cellulose derivative; (b) at least one lipase inhibitor in an amount effective for treating adiposity; and (c) at least one swellable diluent or filler, selected from microcrystalline cellulose, corn starch, or Starch 1500.

2. The composition according to claim 1 which further comprises a disintegrating agent.

3. The composition according to claim 2 which further comprises a wetting agent, and/or a lubricating agent.

4. The composition according to claim 3 which further comprises a binding agent.

5. The composition according to claim 1 wherein the diluent is microcrystalline cellulose and is present in a ratio of methylcellulose to microcrystalline cellulose from about 2.1 to about 14:1.

6. The composition according to claim 1 wherein the diluent is corn starch and is present in a ratio of methylcellulose to cornstarch of from about 7.5 to about 15:1.

7. A a process for preparing a tablet formulation which process comprises: a) blending together to form an intragranular mixture high viscosity methylcellulose of >3000 cps; a diluent selected from microcrystalline cellulose, corn starch, or Starch 1500, or a mixture thereof, a lipase inhibitor, a lubricating agent and optionally a disintegrant; and b) adding to the mixture of step (a), a PVP aqueous solution, or alternatively spraying the mixture of step (a) with a PVP aqueous solution; and preparing granulates; and c) blending together an extragranular mixture of a wetting agent; a lubricating agent; a diluent; and a disintegrant, or a mixture thereof; and d) compacting the granulates of step (b) with the extragranular mixture of step (c).

8. The process according to claim 7 wherein the admixture of the lipase inhibitor is added in step c) rather than step a).

9. A process for the manufacture of a pharmaceutical tablet, which process comprises mixing a) granulates comprising high viscosity methylcellulose of >3000 cps; at least one edible calcium salt, or mixtures thereof; a lipase inhibitor, and optionally together with an intragranular disintegrant, and/or wetting agent, and/or colouring agent; with b) adding to the mixture of step (a), a PVP aqueous solution, or alternatively spraying the mixture of step (a) with a PVP aqueous solution; and preparing granulates; and c) blending together an extragranular mixture of a wetting agent; a lubricating agent; a diluent; and a disintegrant, or a mixture thereof; and d) compacting the granulates of step (b) with the extragranular mixture of step (c).

10. The process according to claim 7 wherein the admixture of the lipase inhibitor is added in step c) rather than step a).

Assignments (1)
CHANGE OF NAME Recorded Jan 8, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023750/0387 →
Continuity (2)
Continuation 0978651800
Related Publication 20030232077A1 · Dec 18, 2003